10:00 am
Providing the Latest Insights into the Mechanism of Action of Anti-TIGIT Targeting Therapies to Inform Effective Combination Strategies & Future Development Settings
Vijay Kuchroo
Director Evergrande Center for Immunologic Diseases, Harvard Medical School and Brigam and Women's Hospital
10:30 am
Exploiting TIGIT’s Mechanism to Target Glioblastoma
Michael Lim
Chair of Neurosurgery, Stanford University
11:00 am
Morning Refreshments & Speed Networking
FcγR-Binding – Developing this Important Functional Attribute for Immune Checkpoint Antibodies
11:30 am
Targeting TIGIT: Which Cell Populations are Modulated by FcγR Engagement?